Copper-Lowering Therapy With Tetrathiomolybdate for Cancer and Diseases of Fibrosis and Inflammation

Journal of Trace Elements in Experimental Medicine

Volumn 16, Issue 4, 2003, Pages 191-199

  Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antiangiogenesis; Anticopper drugs; Cytokines; Transforming growth factor beta; Tumor necrosis factor alpha; Wilson's disease

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; COPPER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRANSFORMING GROWTH FACTOR BETA; TRIENTINE; TUMOR NECROSIS FACTOR ALPHA; ZINC;

ANEMIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CONFERENCE PAPER; COPPER DEFICIENCY; COPPER METABOLISM; DRUG EFFICACY; FIBROSIS; HUMAN; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LUNG FIBROSIS; NONHUMAN; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SIDE EFFECT; TUMOR VASCULARIZATION; WILSON DISEASE;

ANIMALIA; RODENTIA;

EID: 0242442455     PISSN: 0896548X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jtra.10045     Document Type: Conference Paper

References (53)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Eng J Med 1971;285:1182-1186.
2. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 1986;46:467-473.
3. Folkman J, Klagsburn M. Angiogenic factors. Science 1987;235:442-447.
4. Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 1999;6:436-458.
5. Gradishar WJ. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Invest New Drugs 1997;15:49-59.
6. Susman E. Consensus panel: Antiangiogenesis drugs unlikely as single agents. Oncol Times, June 2001.
7. Susman E. San Antonio Breast cancer symposium. Prediction: Shutting down cancer blood vessels still years away. Oncol Times, April 2002.
8. Dotts T. Is angiogenesis inhibition the future of cancer treatment? Hem/Onc Today March 2002.
9. Beckner ME. Factors promoting tumor angiogenesis. Cancer Invest 1999;17:594-623.
10. Parke A, Battacherjee P, Palmer RM, Lazarus NR. Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am J Clin Pathol 1988;137:1121-1142.
11. Raju KS, Alesandrii G, Zinche M, Gullino PM. Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst 1982;69:1183-1188.
12. 1 and copper in angiogenesis. J Natl Cancer Inst 1982;69:475-448.
13. Brem SS, Zagzag D, Tsanaclis AMC, Gatley S, Elkouby MP, Brein SE. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 1990;137:1121-1147.
14. Brem S, Tsanaclis AM, Zagzag D. Anticopper treatment inhibits pseudopdial protrusion and invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery 1990;26:391-396.
15. Brewer GJ. Recognition, diagnosis and management of Wilson's disease. Proc Soc Exp Biol Med 2000;223:39-49.
16. Brewer, GJ. Wilson's Disease: a clinician's guide to recognition, diagnosis, and management. Boston: Kluwer Academic Publishers; 2001.
17. Walshe JM. Penicillamine. A new oral therapy for Wilson's disease. Am J Med 1956;21:487-95.
18. Brewer G, Terry C, Aisen A, Hill G. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987;44:490-493.
19. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dichloride. Lancet 1982;1:643-647.
20. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. The Treatment of Wilson's Disease with Zinc XV. Long-Term Follow-up Studies. J Lab Clin Med 1998;132:264-278.
21. Schouwink G. De hepatocerebrale degeneratie, me een onderzoek naar de zinktofwisseling. University of Amsterdam: MD Thesis 1961.
22. Brewer GJ, Brewer LF, Prasad, AS. Suppression of irreversibly sickled erythrocytes by zinc therapy in sickle cell anemia. J Lab Clin Med 1977;90:549-554.
23. Brewer GJ, Schoomaker EB, Leichtman DA, Kruckleberg WC, Brewer LF, Myers N. The uses of pharmacologic doses of zinc in the treatment of sickle cell anemia. In: Brewer GJ, and Prasad AS, editors. Zinc metabolism: current aspects in health and disease. New York: Allan R. Liss, Inc; 1977. p 241-258.
24. Prasad AS, Brewer GJ, Schoomaker EB, Rabbini P. Hypocupremia induced by zinc therapy in adults. JAMA 1978;240:2166-2168.
25. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins RJ, Brewer GJ. The treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992;120:380-386.
26. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tankanow R, Young AB, Kluin KJ. Initial Therapy of Wilson's Disease patients with Tetrathiomolybdate. Arch Neurol 1991;48:42-47.
27. Brewer GJ, Dick RD, Johnson V, Wang, Yuzbasiyan-Gurkan V, Kluin K, Fink JK, Aisen A. Treatment of Wilson's disease with tetrathiomolybdate I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994;51:545-554.
28. Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA: Treatment of Wilson's disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up on zinc therapy. Arch Neurol 1996;53:1017-1025.
29. Brewer GJ, Hedera P, Kluin KJ, Carlson MD, Askari F, Dick RB, Sitterly JA; Fink JK. Treatment of Wilson's disease with tetrathiomolybdate III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003;60:378-385.
30. Harper PI, Walshe JM. Reversible pancytopenia secondary to treatment with tetrathiomolybdate. Br J Haematol 1986;64:851-853.
31. McQuaid A, Mason J. A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro: the implications for Wilson's disease therapy. J Inorg Biochem 1991;41:87-92.
32. Mills CF, El-Gallad TT, Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorgan Biochem 1981;14:189-207.
33. Bremner I, Mills CF, Young BW. Copper metabolism in rats given di- or trithiomolybdates. J Inorgan Biochem 1982;16:109-119.
34. Mills CF, El-Gallad TT, Bremner I, et al. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorgan Biochem 1981;14:163-175.
35. Gooneratne SR, Howell JM, Gawthorne JM. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br J Nutr 1981;46:469-480.
36. Pan Q, Kleer C, van Golen K, Irani J, Bottema K, Bias C, De Carvalho M, Mesri E, Robins D, Dick R, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62:4854-4859.
37. Cox C, Teknos T, Barrios M, Brewer G, Dick R, Merajver S. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001;111:696-701.
38. Khan M, Miller M, Taylor J, Navkiranjit K, Dick R, van Golen K, Brewer G, Merajver S. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 2002;4:7.
39. van Golen K, Bao L, Brewer G, Pienta K, Karadt J, Livant D, Merajver S. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia 2002;4:373-379.
40. Brewer G, Dick R, Grover D, LeClaire V, Tseng M, Wicha M, Pienta K, Redman B, Thierry J, Sondak V, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6:1-10.
41. Khalil N, Greenberg AH. The role of TGF-beta in pulmonary fibrosis. Ciba Found Symp 1991;157:194-211.
42. Border WA, Noble NA. Mechanisms of disease: transforming growth factor (Beta) in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
43. Denis M. Neutralization of transforming growth factor-beta 1 in a mouse model of immune-induced lung fibrosis. Immunology 1994;82:584-590.
44. Lasky JA, Ortiz LA, Tonthat B, Hoyle GW, Corti M, Athas G, et al. Connective tissue growth factor mRNA expression is unregulated in bleomycin-induced lung fibrosis. Am Physiol Soc 1998;L365-L371.
45. Brigstock DR. The Connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 1999;20:189-206.
46. Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor);. Expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999;21:693-700.
47. Pittet JF, Griffiths MJD, Geiser T, Kaminski N, Dalton SL, Huang X, et al. TGF-β is critical mediator of acute lung injury. J Clin Invest 2001;107:1537-1544.
48. Francki A, Bradshaw AD, Bassuk JA, Howe CC, Couser WG, Sage EH. SPARC regulates the expression of collagen type I and transforming growth factor-β1 in mesangial cells. J Leukoc Biol 1999;22:32145-32152.
49. Strandjord TP, Madtes DK, Weiss DJ, Sage EH. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am Physiol Soc 1999;L628-L635.
50. Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 1994;125:929-943.
51. Brewer G, Phan S. Tetrathiomolybdate anticopper therapy protects against bleomycin-pulmonary fibrosis in mice. J Invest Med 2002;50:227A.
52. Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, Phan SH. Tetrathiomolybdate therapy protects against bleomycin-pulmonary fibrosis in mice. J Lab Clin Med 2003;141:210-216.
53. Askari F, Brewer G. Tetrathiomolybdate anticopper therapy protects against concanavalin A liver damage in mice. J Invest Med 2002;50:220A.